首都医科大学学报 ›› 2025, Vol. 46 ›› Issue (4): 702-709.doi: 10.3969/j.issn.1006-7795.2025.04.018

• 临床研究 • 上一篇    下一篇

急性缺血性脑卒中患者血清糖蛋白非转移性黑色素瘤蛋白B蛋白浓度与疾病严重度及预后的相关性分析

郭宇1,陈伟观2,3,周三连2,3,汤莉巧1,孙王妍1, 张冬梅4,卢红建2,3*   

  1. 1.南通大学护理与康复学院 南通大学第二附属医院,江苏南通 226007; 2.南通市第一人民医院康复医学科,江苏南通 226001;3.南通大学第二附属医院康复医学科,江苏南通 226001; 4.南通大学第二附属医院临床医学研究中心,江苏南通 226001
  • 收稿日期:2024-12-13 出版日期:2025-08-21 发布日期:2025-09-01
  • 通讯作者: 卢红建 E-mail:Dr_lhj2021@126.com
  • 基金资助:
    国家重点研发计划项目(2022YFC2405605),江苏省自然科学基金项目(BK20221274),中国高校产学研创新基金项目(华通国康医学科研专项,2023HT042)。

Correlation between serum glycoprotein non-metastatic melanoma protein B levels and disease severity and prognosis in patients with acute ischemic stroke

Guo Yu1, Chen Weiguan2,3, Zhou Sanlian2,3, Tang Liqiao1, Sun Wangyan1, Zhang Dongmei4, Lu Hongjian2,3*   

  1. 1.School of Nursing and Rehabilitation, Affiliated Hospital 2 of Nantong University,Nantong University, Nantong 226007, Jiangsu Province, China;2.Department of Rehabilitation Medicine,Nantong First People's Hospital,Nantong 226001, Jiangsu Province, China; 3.Department of Rehabilitation Medicine, Affiliated Hospital 2 of Nantong University, Nantong 226001, Jiangsu Province, China; 4.Medical Research Center, Affiliated Hospital 2 of Nantong University, Nantong 226001, Jiangsu Province, China
  • Received:2024-12-13 Online:2025-08-21 Published:2025-09-01
  • Supported by:
    This study was supported by National Key Research and Development Program(2022YFC2405605),Natural Science Foundation of Jiangsu Province(BK20221274),China's University Industry Research and Innovation Fund (Huatong Guokang Medical Research Special Project 2023HT042).

摘要: 目的  研究急性缺血性脑卒中(acute ischemic stroke,AIS)患者的血清中糖蛋白非转移性黑色素瘤蛋白B(glycoprotein non-metastatic melanoma protein B,GPNMB)浓度和神经功能损伤程度以及预后的关系,筛选潜在生物标志物,为临床诊治提供参考。方法  选择2023年6月至2024年3月在南通大学第二附属医院神经内科住院治疗的105例AIS患者作为样本群。 入组患者按照入院24 h美国国立卫生研究院脑卒中量表(National Institutes of Health Strobe Scale, NIHSS)评分划分为轻度组(n=42)和中重度组(n=63),以改良Rankin量表(Modified Rankin Scale, mRS)评价出院后3个月功能恢复情况,将样本细分为预后良好组(n=34)和预后不良组(n=71),采用ELISA法检测血清GPNMB蛋白浓度,分析血清GPNMB蛋白浓度与NIHSS、mRS评分的相关性,并用二元Logistic回归模型评估血清GPNMB蛋白浓度对AIS神经功能损害的预测价值和预后评估价值。结果  中重度神经功能损伤及预后不良患者血清GPNMB蛋白浓度明显低于轻度及预后良好组(P<0.05),血清GPNMB蛋白浓度与NIHSS评分呈显著负相关(r=-0.196,P<0.05),与mRS评分也呈显著负相关趋势(r=-0.334,P<0.05)。 多变量回归分析显示,GPNMB依然是AIS的关键独立危险因素(P<0.05),根据受试者工作特征曲线得出的评估结果表明,血清GPNMB蛋白浓度在预测神经功能损伤以及不良预后方面的有诊断价值(灵敏度达到55.6%,特异度为81.8%,准确率是63.81%,P<0.05)。结论  血清GPNMB蛋白浓度降低同AIS患者神经功能损害的程度存在明显的正相关联系,很有可能会成为衡量病情严重程度和长期转归情况的重要生物指标。

关键词: 糖蛋白非转移性黑色素瘤蛋白B, 缺血性脑卒中, 神经功能缺损, 预后, 预测, 美国国立卫生研究院脑卒中量表, 改良Ranbin量表

Abstract: Objective  This study mainly focuses on the relationship between the serum glycoprotein non-metastatic melanoma protein B (GPNMB) concentration and the degree of neurological damage and prognosis in patients with acute ischemic stroke (AIS), and screens potential biomarkers to provide a reference for clinical diagnosis and treatment. Methods  A total of 105 AIS patients hospitalized in the Department of Neurology of the Hospital 2 of Nantong University from June 2023 to March 2024 were selected as the sample group. In this study, the patients were divided into mild group (n=42) and moderate to severe group (n=63) according to the National Institutes of Health Strobe Scale (NIHSS) score within 24 hours of admission. The Modified Rankin Scale (mRS) was used to evaluate the functional recovery 3 months after discharge. The samples were subdivided into good prognosis group (n=34) and poor prognosis group (n=71). The serum GPNMB protein level was detected by ELISA, and the correlation between serum GPNMB protein level and NIHSS and mRS scores was analyzed. The binary Logistic regression model was used to evaluate the predictive value and prognostic evaluation value of serum GPNMB protein level for AIS neurological function damage. Results  The serum GPNMB protein concentration in patients with moderate to severe neurological impairment and poor prognosis was significantly lower than that in patients with mild and good prognosis (P<0.05). The serum GPNMB protein level was significantly negatively correlated with the NIHSS score (r=-0.196, P<0.05) and the mRS score (r=-0.334, P<0.05). Multivariate regression analysis showed that GPNMB was still a key independent risk factor for AIS (P<0.05). The evaluation results obtained based on the receiver operating characteristic curve (ROC) showed that the serum GPNMB protein level had diagnostic value in predicting neurological impairment and poor prognosis (sensitivity reached 55.6%, specificity was 81.8%, and the overall accuracy was 63.81%, P<0.05).Conclusion  There is a significant positive correlation between the decrease in serum GPNMB protein concentration and the degree of neurological damage in AIS patients, and it is likely to become an important biological indicator for measuring the severity of the disease and long-term prognosis.

Key words: glycoprotein non-metastatic melanoma protein B, ischemic stroke, neurological deficit, prognosis, prediction, National Institutes of Health Strobe Scale, Modified Rankin Scale

中图分类号: